Cargando…
The effect of the papillary renal cell carcinoma subtype on oncological outcomes
The study aimed to compare the clinicopathological features and prognosis between type I and type II papillary renal cell carcinoma (PRCC) and to investigate whether the subtypes of PRCC would affect oncological outcomes. A total of 102 patients with PRCC were recruited, of which 42 were type I PRCC...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713298/ https://www.ncbi.nlm.nih.gov/pubmed/33273677 http://dx.doi.org/10.1038/s41598-020-78174-9 |
_version_ | 1783618550390325248 |
---|---|
author | Pan, Honghong Ye, Liefu Zhu, Qingguo Yang, Zesong Hu, Minxiong |
author_facet | Pan, Honghong Ye, Liefu Zhu, Qingguo Yang, Zesong Hu, Minxiong |
author_sort | Pan, Honghong |
collection | PubMed |
description | The study aimed to compare the clinicopathological features and prognosis between type I and type II papillary renal cell carcinoma (PRCC) and to investigate whether the subtypes of PRCC would affect oncological outcomes. A total of 102 patients with PRCC were recruited, of which 42 were type I PRCC and 60 type II. The clinicopathological features and oncologic outcomes of the patients were evaluated. The type II cases had a higher WHO/ISUP grading (P < 0.001), T (P = 0.003), N (P = 0.010) stage and stage grouping (P = 0.011) than the type I. During a median follow-up period of 61.4 months, 1-year cancer specific survival (CSS) of the type I was 100%, 5-year CSS was 95.2%, the 1-year CSS of the type II was 96.2%, and 5-year CSS was 75.7%. The univariate analysis showed that subtype, symptoms, TNM, stage grouping, WHO/ISUP grading and surgical methods appeared to affect prognosis of the patients with PRCC. However, multivariate analysis revealed that only stage grouping was the independent risk factor. After the stage grouping factor was adjusted for the analysis, there were no statistically significant differences in CSS (P = 0.214) and PFS (P = 0.190) between the localized type I and type II PRCC groups. Compared with type I PRCC, type II had higher pathological T, N stage and WHO/ISUP grading. However, it was the Stage grouping that made a great difference to oncological outcomes, rather than the subtype of PRCC. |
format | Online Article Text |
id | pubmed-7713298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77132982020-12-03 The effect of the papillary renal cell carcinoma subtype on oncological outcomes Pan, Honghong Ye, Liefu Zhu, Qingguo Yang, Zesong Hu, Minxiong Sci Rep Article The study aimed to compare the clinicopathological features and prognosis between type I and type II papillary renal cell carcinoma (PRCC) and to investigate whether the subtypes of PRCC would affect oncological outcomes. A total of 102 patients with PRCC were recruited, of which 42 were type I PRCC and 60 type II. The clinicopathological features and oncologic outcomes of the patients were evaluated. The type II cases had a higher WHO/ISUP grading (P < 0.001), T (P = 0.003), N (P = 0.010) stage and stage grouping (P = 0.011) than the type I. During a median follow-up period of 61.4 months, 1-year cancer specific survival (CSS) of the type I was 100%, 5-year CSS was 95.2%, the 1-year CSS of the type II was 96.2%, and 5-year CSS was 75.7%. The univariate analysis showed that subtype, symptoms, TNM, stage grouping, WHO/ISUP grading and surgical methods appeared to affect prognosis of the patients with PRCC. However, multivariate analysis revealed that only stage grouping was the independent risk factor. After the stage grouping factor was adjusted for the analysis, there were no statistically significant differences in CSS (P = 0.214) and PFS (P = 0.190) between the localized type I and type II PRCC groups. Compared with type I PRCC, type II had higher pathological T, N stage and WHO/ISUP grading. However, it was the Stage grouping that made a great difference to oncological outcomes, rather than the subtype of PRCC. Nature Publishing Group UK 2020-12-03 /pmc/articles/PMC7713298/ /pubmed/33273677 http://dx.doi.org/10.1038/s41598-020-78174-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Pan, Honghong Ye, Liefu Zhu, Qingguo Yang, Zesong Hu, Minxiong The effect of the papillary renal cell carcinoma subtype on oncological outcomes |
title | The effect of the papillary renal cell carcinoma subtype on oncological outcomes |
title_full | The effect of the papillary renal cell carcinoma subtype on oncological outcomes |
title_fullStr | The effect of the papillary renal cell carcinoma subtype on oncological outcomes |
title_full_unstemmed | The effect of the papillary renal cell carcinoma subtype on oncological outcomes |
title_short | The effect of the papillary renal cell carcinoma subtype on oncological outcomes |
title_sort | effect of the papillary renal cell carcinoma subtype on oncological outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713298/ https://www.ncbi.nlm.nih.gov/pubmed/33273677 http://dx.doi.org/10.1038/s41598-020-78174-9 |
work_keys_str_mv | AT panhonghong theeffectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT yeliefu theeffectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT zhuqingguo theeffectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT yangzesong theeffectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT huminxiong theeffectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT panhonghong effectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT yeliefu effectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT zhuqingguo effectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT yangzesong effectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes AT huminxiong effectofthepapillaryrenalcellcarcinomasubtypeononcologicaloutcomes |